https://www.youtube.com/watch?v=tauDDGGvpQU SOURCE: Midas Letter Live March 27, 2019 -- Medexus Pharmaceuticals Inc (CVE:MDP) (FRA:P731) CEO Ken d’Entremont provides an overview of the company and highlights its recent financial reporting. The company is the results of the recent amalgamation of three specialty pharmaceutical companies: Pediapharm Inc, Medexus Inc, and Medac Pharma. As d’Entremont...Read the Full Article
VICTORIA, British Columbia (BUSINESS WIRE) -- In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with...Read the Full Article
1st Spine PMA approved by the FDA in more than 3 years15-month PMA approval process vs. 30-month average for Ortho/Spine in the last 10 years WASHINGTON (PRNewswire) -- On March 7, 2019, MCRA, LLC announced its role in the successful Premarket Approval (PMA) application decision by the U.S. Food and Drug Administration (FDA)...Read the Full Article
SUMMIT, N.J. (PRNewswire) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience a predictable pattern of epileptic seizures, today announced it will present clinical data from the open-label portion of the randomized Phase 2b StATES Study (Staccato Alprazolam Terminates Epileptic Seizures) at the...Read the Full Article
IRVINE, Calif., -- Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of the...Read the Full Article
LOS ANGELES, March 8, 2019 /CNW/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa's shareholders to create a company focused on the development of innovative therapeutics for...Read the Full Article
SOURCE: Forbius This trial will evaluate the efficacy of AVID100 in SCCHN patients with EGFR IHC 3+ tumorsAVID100 is the most advanced, broadly active anti-EGFR ADC in clinical development20% of SCCHN patients highly overexpress EGFR; no therapy is approved for these patients Austin, TX, and Montreal, QC (Mar. 7, 2019) – Forbius,...Read the Full Article
Alan Milinazzo, Partner, Global Healthcare and Life Sciences Practice - Heidrick & Struggles (PRNewsFoto/Heidrick & Struggles) Quebec City, Quebec, March 4, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. “We are delighted to see Alan, a renowned leader...Read the Full Article
SOURCE: Forbius This trial will evaluate the safety and anti-fibrotic effects of AVID200 in diffuse cutaneous systemic sclerosis patientsAVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3TGF-beta 1 & 3 are the principal drivers of fibrosis in systemic sclerosis and other indications, supporting broad utility of AVID200 Austin,...Read the Full Article
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or...Read the Full Article
SOURCE: Forbius MPN-RC sponsored, NIH-supported Phase 1/2 trial in myelofibrosis to commence imminentlyTGF-beta is a central driver of bone marrow fibrosis in myelofibrosisAVID200 selectively inhibits TGF-beta 1 & 3, the principal fibrotic TGF-beta isoforms, while sparing TGF-beta 2, a positive regulator of hematopoiesis Austin, TX and Montreal, QC (Feb. 14, 2019) –...Read the Full Article
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT at Week 4 Primary endpoint of drop discomfort at 1-minute on Day 1 showed no statistical difference between VOS and Restasis®, as both exhibited...Read the Full Article
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company (“Lilly”). In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0...Read the Full Article
Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Carmelo Mastrandrea as the company’s Vice President of Sales. Mr. Carmelo...Read the Full Article
SOURCE: Forbius AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitorBest-in-class efficacy and safety potential by selectively targeting principal oncogenic TGF-beta isoformsReverses immunosuppression and renders tumors sensitive to checkpoint blockade in pre-clinical models Jan. 7, 2019 – Forbius, a clinical-stage company developing biologics for the treatment of cancer...Read the Full Article
Veteran Life Sciences Executive Brings Proven Experience Developing CNS Therapeutics MONTREAL and TORONTO, Jan. 4, 2019 /CNW/ - KalGene Pharmaceuticals Inc., a biotechnology company developing therapeutics to slow the progression of Alzheimer's disease, today announced the appointment of James Callaway, Ph.D. as chief executive officer, effective immediately. "This has been a very...Read the Full Article
SOURCE: Endotronix, Inc. LISLE, Ill., Jan. 3, 2019 - Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President of Sales and Marketing. Mr. Yearick will oversee Endotronix's...Read the Full Article
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a major medical meeting in 2019 NEW ORLEANS, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Engage Therapeutics today announced from the American Epilepsy...Read the Full Article
International Group of Investors from Canada, the U.S. and China Support Former Senior Executives from Pharmasset and Idenix in New Venture ATLANTA, Nov. 27, 2018 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios") today announced the completion of a US$25 million oversubscribed Series A financing led by Lumira Ventures and Domain Associates, two prominent...Read the Full Article
Exact Imaging's Novel ExactVu™ Micro-Ultrasound System is Helping Urologists Worldwide Revolutionize Prostate Cancer Detection TORONTO, Nov. 22, 2018 /PRNewswire/ - Exact Imaging, the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, proudly announces this it has been chosen as Life Science Ontario (LSO)'s 2019 Life Science Company of the Year....Read the Full Article
Individuals Treated with TPS lost 3-fold More Weight Than Those in Sham-Controlled Placebo Arm SAN CARLOS, Calif., Nov. 15, 2018 /PRNewswire/ -- BAROnova, Inc., a clinical stage medical device company focused on the development of non-surgical solutions for the treatment of obesity, announced today the presentation of primary results of its pivotal trial,...Read the Full Article
QUEBEC CITY, Nov. 1, 2018 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve ("FFR") to diagnose and treat cardio vascular disease. The use of pressure guidewires to measure...Read the Full Article
With Reimbursement in Place and Positive Late-Breaking Data, Company Expects Continued Growth in Germany Kirkland, Wash. – October 18, 2018 – Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced that InEK, the German Institute for the Hospital...Read the Full Article
-Target enrollment has been exceeded and completed ahead of schedule -Company anticipates primary data analysis in Q4 2019 VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of...Read the Full Article
In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume KIRKLAND, Wash.- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, announced results of the company’s landmark REDUCE FMR clinical trial, which...Read the Full Article
September 19, 2018 06:45 AM Eastern Daylight Time VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting...Read the Full Article
KIRKLAND, Wash.- Cardiac Dimensions, Inc. a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the company has randomized its first patient in the CARILLON Pivotal Trial. The CARILLON Trial is evaluating the Carillon® Mitral Contour System® for the treatment of functional...Read the Full Article
G1 Therapeutics (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its randomized Phase 2 trial of trilaciclib in combination with chemotherapy and Tecentriq® (atezolizumab) in first-line small cell lung cancer (SCLC). Myelopreservation results from the trial will be reported in the fourth quarter of 2018....Read the Full Article
(Above) The Cordella™ SystemSOURCE: Endotronix, Inc. Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture Partners, BioVentures Investors, Lumira...Read the Full Article
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Garry Nicholson has been appointed to its board of directors, effective September 12, 2018. “We are pleased to welcome Garry as an independent director to our board. He has a breadth of experience in oncology development and commercialization, including leading the global regulatory and...Read the Full Article
ExactVu™ micro-ultrasound platform - now with FusionVu - enables the highest real-time resolution for targeted prostate imaging and biopsy Exact Imaging, the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has received Health Canada approval for its FusionVu™ application for micro-ultrasound/MRI fusion...Read the Full Article
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an...Read the Full Article
Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). The IASD is the world's first transcatheter device for heart failure with preserved (HFpEF) and mid-range (HFmrEF) ejection...Read the Full Article
Forbius announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for AVID200, an isoform-selective TGF-β inhibitor. This enables the company to begin a Phase 1 clinical study to evaluate AVID200 as a potential treatment for diffuse cutaneous systemic sclerosis (SSc), a life-threatening fibrotic disease. SSc is a rare, severe, and...Read the Full Article
Forbius (Formation Biologics) announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support operations and Phase 2a development of AVID100, a highly potent anti-EGFR antibody-drug conjugate, in three cancer indications with significant unmet medical...Read the Full Article
August 16, 2018 External LinkRead the Full Article
Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing the acebilustat Phase 3 clinical program ATLANTA – Celtaxsys, Inc., a clinical...Read the Full Article
(Reuters) - Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. There are few treatment options for the 70,000 cystic fibrosis patients worldwide, who rarely live beyond...Read the Full Article
VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s second quarter 2018 financial results and provide a general business update. The conference call...Read the Full Article
Relationship allows UroGPO’s 550+ Member Practices across the USA to access the ExactVu™ Micro-Ultrasound Platform TORONTO, CANADA - Exact Imaging, the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced today that it has become a UroGPO Imaging Partner. UroGPO is the preeminent urology specific...Read the Full Article
SAN CARLOS, Calif., /PRNewswire/ -- BAROnova, Inc., announced today that it has submitted a Pre-Market Approval (PMA) application for the TransPyloric Shuttle device intended for the treatment of obesity to the Food and Drug Administration (FDA). Obesity is a worldwide epidemic with over 40% of adult Americans suffering from obesity and its attendant co-morbidities. ...Read the Full Article
MONTRÉAL and BOSTON, /CNW/ - enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including the Gene Pill™ , today announced the appointment of Jason D. Hanson as President, Chief Executive Officer and Director. Mr. Hanson will succeed enGene co-founder Anthony Cheung, Ph.D., who will assume...Read the Full Article
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES). VOS, which is a proprietary nanomicellar formulation, enables high concentrations...Read the Full Article
SOUTH SAN FRANCISCO, California, /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management. Sirona Capital, along with existing investors Canaan Partners, Sofinnova Ventures, Brace Pharma Capital,...Read the Full Article
RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel. “We...Read the Full Article
Source: Life Science Leader By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein The Enterprisers: Life Science Leadership In Action External LinkRead the Full Article
IN 2016, AN ESTIMATED 564,000 CANADIANS SUFFERED FROM DEMENTIA. By 2031, says the Alzheimer’s Society of Canada, that figure will rise to 937,000. In the US it is estimated that the Alzheimer’s burden will triple from 5.3 million people today to 16 million by 2050. Worldwide, nearly 44 million people have or...Read the Full Article
As life expectancies around the globe continue to go up, the accompanying steady rise in senior populations has given way to a newly intensified global focus on dementia in recent years. Dr. Margaret Chan, director-general of the World Health Organization, underscored the urgency of current and future needs in her 2015 address to...Read the Full Article
SOURCE: Endotronix, Inc. LISLE, Ill., June 28, 2018 /PRNewswire/ -- Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced they have joined the American Heart Association's Center for Health Technology & Innovation's (CHTI) Innovators Network. The collaboration allows Endotronix to integrate the Association's digital resources into the Cordella™...Read the Full Article
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis (FSGS). The first patients have...Read the Full Article